Adaptimmune Ther ADR (ADAP)

$0.27 -0.01 (-2.08%)
Market Cap 72.70M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio -0.68
Volume 317,700
Avg Vol 1,023,882
Day's Range N/A - N/A
Shares Out 265.05M
Stochastic %K 70%
Beta 2.18
Analysts Sell
Price Target $1.51

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
Mogeyman
Mogeyman Jul. 12 at 12:50 PM
$ADAP
0 · Reply
Avj90
Avj90 Jul. 12 at 8:44 AM
$ADAP 0
1 · Reply
leonardi
leonardi Jul. 11 at 10:43 PM
$ADAP if financing is sorted can we agree this goes overnight $2
1 · Reply
Investmann
Investmann Jul. 11 at 6:36 PM
$ADAP something big is coming
2 · Reply
sportif
sportif Jul. 11 at 5:48 PM
$ADAP Short interest in Adaptimmune Therapeutics (ADAP) recently dropped by 14.6%, now sitting at around 1.97% of the float. The current short interest ratio is approximately 3.1 days to cover. This indicates a moderate bearish sentiment, but the decline suggests some shorts may be starting to exit.
1 · Reply
sportif
sportif Jul. 11 at 5:37 PM
$ADAP Time to buy
0 · Reply
JJmcnasty
JJmcnasty Jul. 11 at 11:22 AM
$ADAP maybe they need a “go fund me” page just to squeeze out another quarter
1 · Reply
zed_rickel
zed_rickel Jul. 11 at 12:09 AM
$ADAP so they are pretty much out of money by now right? Last ER they reported about 60M liquid on March 31, burn about 50M a quarter, and let's say they pulled in 10M of q2 revenue. They must be running on fumes, are we expecting something imminent or will they make it another month until the next ER without announcing any funding?
4 · Reply
mrdoing
mrdoing Jul. 10 at 9:39 PM
$ADAP NOW
0 · Reply
Joe__321
Joe__321 Jul. 10 at 6:04 PM
$ADAP nice, I miss the bashers. Silly GIF poster
0 · Reply
Latest News on ADAP
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:59 PM EDT - 2 months ago

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 2 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

May 7, 2025, 12:00 PM EDT - 2 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 12:10 PM EDT - 4 months ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 4 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Mar 12, 2025, 4:54 PM EDT - 4 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 30, 2025, 4:00 PM EST - 5 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Jan 13, 2025, 8:00 AM EST - 6 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 19, 2024, 7:30 AM EST - 7 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dec 2, 2024, 4:00 PM EST - 7 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:48 PM EST - 8 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 8 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 13, 2024, 9:00 AM EST - 8 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Nov 5, 2024, 9:19 AM EST - 8 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Oct 31, 2024, 5:20 PM EDT - 9 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Adaptimmune to Participate in Two Bank Conferences this September

Aug 28, 2024, 8:00 AM EDT - 11 months ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 11:42 AM EDT - 11 months ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 11 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 2, 2024, 9:20 AM EDT - 1 year ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Aug 1, 2024, 8:20 PM EDT - 1 year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 3, 2024, 9:54 AM EDT - 1 year ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 17, 2024, 2:05 PM EDT - 1 year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Dec 6, 2023, 7:00 AM EST - 1 year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:45 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:30 AM EST - 1 year ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Nov 8, 2023, 7:05 AM EST - 1 year ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Oct 25, 2023, 8:06 AM EDT - 1 year ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Oct 23, 2023, 4:15 AM EDT - 1 year ago

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Adaptimmune: Spinning Sarcoma Into Gold

Sep 12, 2023, 8:48 AM EDT - 1 year ago

Adaptimmune: Spinning Sarcoma Into Gold

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Mogeyman
Mogeyman Jul. 12 at 12:50 PM
$ADAP
0 · Reply
Avj90
Avj90 Jul. 12 at 8:44 AM
$ADAP 0
1 · Reply
leonardi
leonardi Jul. 11 at 10:43 PM
$ADAP if financing is sorted can we agree this goes overnight $2
1 · Reply
Investmann
Investmann Jul. 11 at 6:36 PM
$ADAP something big is coming
2 · Reply
sportif
sportif Jul. 11 at 5:48 PM
$ADAP Short interest in Adaptimmune Therapeutics (ADAP) recently dropped by 14.6%, now sitting at around 1.97% of the float. The current short interest ratio is approximately 3.1 days to cover. This indicates a moderate bearish sentiment, but the decline suggests some shorts may be starting to exit.
1 · Reply
sportif
sportif Jul. 11 at 5:37 PM
$ADAP Time to buy
0 · Reply
JJmcnasty
JJmcnasty Jul. 11 at 11:22 AM
$ADAP maybe they need a “go fund me” page just to squeeze out another quarter
1 · Reply
zed_rickel
zed_rickel Jul. 11 at 12:09 AM
$ADAP so they are pretty much out of money by now right? Last ER they reported about 60M liquid on March 31, burn about 50M a quarter, and let's say they pulled in 10M of q2 revenue. They must be running on fumes, are we expecting something imminent or will they make it another month until the next ER without announcing any funding?
4 · Reply
mrdoing
mrdoing Jul. 10 at 9:39 PM
$ADAP NOW
0 · Reply
Joe__321
Joe__321 Jul. 10 at 6:04 PM
$ADAP nice, I miss the bashers. Silly GIF poster
0 · Reply
Mogeyman
Mogeyman Jul. 10 at 9:59 AM
$ADAP
1 · Reply
Bionco
Bionco Jul. 10 at 9:52 AM
$ADAP If each of the 17 active ATCs performed apheresis on at least one patient, the total sales revenue in Q2 would exceed expectations and surprise everyone.😄
2 · Reply
GickyRervais
GickyRervais Jul. 10 at 2:44 AM
$ADAP Massive spike in options volume today +300%
0 · Reply
Bionco
Bionco Jul. 10 at 12:49 AM
$ADAP Dana-Farber Cancer Institute now is active
2 · Reply
leonardi
leonardi Jul. 10 at 12:16 AM
$ADAP maybe no one considering this but what if they really suprise everyone with sales this qtr? Some atc did say they had waitlist in previous qtr
2 · Reply
quantit8
quantit8 Jul. 9 at 9:53 PM
$ADAP
0 · Reply
mrdoing
mrdoing Jul. 9 at 9:52 PM
$ADAP 😎🍾
0 · Reply
Sven_Bonn
Sven_Bonn Jul. 9 at 6:59 PM
$ADAP nice… Adrian, give us some news….
0 · Reply
GickyRervais
GickyRervais Jul. 9 at 6:32 PM
$ADAP Wow. $0.2725. If this thing hits $0.2781 then it’ll rip to $0.2835.
3 · Reply
Polip
Polip Jul. 9 at 3:26 PM
$ADAP is close to announce strategic alternative deal
1 · Reply
Whtmtn
Whtmtn Jul. 9 at 11:45 AM
$ADAP anyone hear recall the Steve Miller band and their song “fly like an eagle?” Time keeps on slippin…
1 · Reply
Mogeyman
Mogeyman Jul. 9 at 11:00 AM
$ADAP Closing in.
2 · Reply